258 related articles for article (PubMed ID: 24611519)
1. Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications.
Zhang S; Shu X; Tian X; Chen F; Lu X; Wang G
Clin Exp Immunol; 2014 Jul; 177(1):134-41. PubMed ID: 24611519
[TBL] [Abstract][Full Text] [Related]
2. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
[TBL] [Abstract][Full Text] [Related]
3. [Neutrophil extracellular traps-induced endothelial cell damage in the pathogenesis of dermatomyositis-associated interstitial lung disease].
Zhang Y; Yan B; Liu Y
Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):650-654. PubMed ID: 28870032
[No Abstract] [Full Text] [Related]
4. Interstitial lung disease in polymyositis and dermatomyositis.
Marie I; Hachulla E; Chérin P; Dominique S; Hatron PY; Hellot MF; Devulder B; Herson S; Levesque H; Courtois H
Arthritis Rheum; 2002 Dec; 47(6):614-22. PubMed ID: 12522835
[TBL] [Abstract][Full Text] [Related]
5. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease in polymyositis and dermatomyositis.
Chen IJ; Jan Wu YJ; Lin CW; Fan KW; Luo SF; Ho HH; Liou LB; Tsai WP; Chen JY; Yang CH; Kuo CF; Yu KH
Clin Rheumatol; 2009 Jun; 28(6):639-46. PubMed ID: 19247576
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics and Risk Factors of Polymyositis and Dermatomyositis Combined with Interstitial Lung Disease in Patients Residing in the Northeast Sichuan Province of China.
Li T; Tang ZY; Zhang QB; Xiao FN; Jian GL; Xie Y; Guo JW; Qing YF
Curr Rheumatol Rev; 2023; 19(4):455-462. PubMed ID: 37005523
[TBL] [Abstract][Full Text] [Related]
10. Interstitial lung disease in polymyositis and dermatomyositis.
Hirakata M; Nagai S
Curr Opin Rheumatol; 2000 Nov; 12(6):501-8. PubMed ID: 11092199
[TBL] [Abstract][Full Text] [Related]
11. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
[TBL] [Abstract][Full Text] [Related]
12. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis.
Fathi M; Barbasso Helmers S; Lundberg IE
J Intern Med; 2012 Jun; 271(6):589-97. PubMed ID: 21950266
[TBL] [Abstract][Full Text] [Related]
13. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
[No Abstract] [Full Text] [Related]
14. Inflammatory biomarkers in polymyositis/dermatomyositis patients with interstitial lung disease: a retrospective study.
Zhao J; Guo XJ; Shi L
Curr Med Res Opin; 2024 Jan; 40(1):113-122. PubMed ID: 37938089
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020.
Sun KY; Fan Y; Wang YX; Zhong YJ; Wang GF
Semin Arthritis Rheum; 2021 Feb; 51(1):175-191. PubMed ID: 33383294
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study.
Ji SY; Zeng FQ; Guo Q; Tan GZ; Tang HF; Luo YJ; Tang ZQ; Han YF
Chin Med J (Engl); 2010 Mar; 123(5):517-22. PubMed ID: 20367973
[TBL] [Abstract][Full Text] [Related]
17. [Measurement and clinical significance of serum monocyte chemoattractant protein-1 in patients with polymyosits/dermatomyosits].
Chen F; Shu XM; Wang DX; Wang GC; Lu X
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Apr; 44(2):204-8. PubMed ID: 22516988
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of antineutrophil cytoplasmic antibody positivity on the occurrence of interstitial lung disease in patients with polymyositis/dermatomyositis.
Ha JW; Pyo JY; Ahn SS; Song JJ; Park YB; Lee SW
Ann Palliat Med; 2022 Oct; 11(10):3181-3192. PubMed ID: 36226644
[TBL] [Abstract][Full Text] [Related]
19. Anti-Jo-1 antibody in patients with polymyositis/dermatomyositis.
Leu CC; Lan JL
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1992 Feb; 25(1):41-7. PubMed ID: 1306148
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study.
Nakazawa M; Kaneko Y; Takeuchi T
Clin Rheumatol; 2018 Mar; 37(3):765-771. PubMed ID: 28975463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
